A quick turnaround in approvals for clinical trials and quality work has given Beltas Clinical Research a growing reputation internationally.
The nine-year old Auckland company manages clinical trials in hospitals and clinics throughout Australasia and Europe for mainly North American clients.
The sector was estimated to be worth up to $20 billion dollars in 2008 and is growing at 10% - 15% per year.
Managing director Gerard Dunne says Beltas is attracting high quality medical research by holding world-class standards and keeping costs down by getting the trials approved quickly.
He says companies in the United States are often a little bit sceptical, but they keep coming back and Beltas conmtinues to grow.
However, other countries also addressing speedy approval of trials, but Mr Dunne says New Zealand is still in front.